Estimated Burden of Cardiovascular Disease and Value-Based Price Range for Evolocumab in a High-Risk, Secondary-Prevention Population in the US Payer Context
Journal of Medical Economics - United Kingdom
doi 10.1080/13696998.2017.1284078
Full Text
Open PDFAbstract
Available in full text
Categories
Date
January 25, 2017
Authors
Publisher
Informa UK Limited